Topical Amitriptyline Gets Fast Track Status for Chemotherapy-Induced Neuropathic Pain
ATX01 is a topical formulation of amitriptyline designed to directly inhibit pain signaling in the nerve fibers on the epidermis and dermis.
Neuropathic Pain
Medtronic’s SCS Therapy Approved for Painful Diabetic Peripheral Neuropathy
These SCS devices were cleared based on data from a randomized controlled trial published in the journal Diabetes Care in 2014.
AAN: Painful Diabetic Neuropathy Treatment Guidelines Updated
Several pharmacotherapies have been shown to reduce pain in patients with painful diabetic neuropathy.
Enrollment in Fibromyalgia Treatment Study Ends After Disappointing Results
The phase 3 RALLY study is evaluating the efficacy and safety of TNX-102 SL in 514 adult patients with fibromyalgia.
FDA Approves Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy
Nevro’s SCS system for painful diabetic neuropathy will be available under the brand name HFX™ for PDN.
Capsaicin 8% Safe and Effective for Diabetic Peripheral Nerve Pain Therapy
Investigators assessed the efficacy and tolerability of a high-concentration capsaicin 8% patch to treat diabetic peripheral nerve pain, either alone or in combination with standard oral therapies.
Qutenza Approved for Painful Diabetic Peripheral Neuropathy of the Feet
The FDA has approved Qutenza® (capsaicin 8% patch; Averitas Pharma) for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet.
Nonopioid Drug Therapies Evaluated for Chronic Pain
Various electronic databases were accessed to obtain randomized controlled trials (RCTs) evaluating nonopioid agents in chronic pain patients. The review focused on 7 chronic pain conditions, including neuropathic pain, fibromyalgia, osteoarthritis, inflammatory arthritis, low back pain, chronic headache, and sickle cell disease.
Lowering Cholesterol Levels May Worsen Nerve Damage in T2DM
Higher number of nerve lesions, declining nerve conduction velocities and amplitudes seen
Decreased Response to Botulinum Toxin Type A Agents Observed Over Time
Preliminary findings showed the decrease in botulinum toxin type A therapeutic effect over time warrants further study.
